机译:基因组和候选基因氯吡格雷疗效方法使用药物动力学和临床终点 - 理性和设计国际氯吡格雷药物同盟(ICPC)
St Antonius Center for Platelet Function Research Department of Cardiology St Antonius Hospital;
Internal Medicine Béziers Hospital France Geneva Platelet Group University of Geneva School of;
Department of Medicine Program for Personalized and Genomic Medicine University of Maryland;
Department of Biomedical Data Science Stanford University;
Department of Medicine Program for Personalized and Genomic Medicine University of Maryland;
Department of Clinical Pharmacology Inje University Busan Paik Hospital;
Heart Center Balatonfüred and Heart and Vascular Center Semmelweis University;
Stroke Pharmacogenomics and Genetics Fundació Docència i Recerca Mútua Terrassa Neurovascular;
Department of Medicine Program for Personalized and Genomic Medicine University of Maryland;
Genomic Medicine Institute Geisinger Health System;
Department of Biomedical Data Science Stanford University;
Neurovascular Research Laboratory Vall d'Hebron Institute of Research;
Department of Experimental and Clinical Medicine University of Florence;
Departments of Medicine and Pharmacology Vanderbilt University School of Medicine;
Cardiovascular Center and Cardiology Division Seoul St. Mary's Hospital College of Medicine The;
Department of Cardiology and Cardiac Catheterization Laboratory Rigshospitalet University of;
University Heart Center Freiburg Bad Krozingen Department of Cardiology and Angiology II;
Departments of Medicine Pharmacology and Biomedical Informatics Vanderbilt University School of;
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart and University of Tübingen;
Department of Biomedical Data Science Stanford University;
Department of Cardiology Patras University Hospital;
Department of Pharmacology and Pharmacogenomics Research Center College of Medicine Inje;
Quebec Heart and Lung Institute;
Department of Cardiology and Cardiovascular Medicine University Hospital Tübingen;
Inova Center for Thrombosis Research and Drug Development. Inova Heart and Vascular Institute;
Department of Cardiology Swiss Cardiovascular Center Bern Bern University Hospital;
Department of Experimental and Clinical Medicine University of Florence Atherothrombotic Diseases;
Cardiology Unit Azienda Ospedaliera Universitria di Ferrara Cona (FE) and Maria Cecilia Hospital;
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart and University of Tübingen;
Department of Cardiology and Cardiac Catheterization Laboratory Rigshospitalet University of;
Division of Cardiology Department of Internal Medicine Chang Gung Memorial Hospital Linkou and;
Department of Pharmacology and Pharmacogenomics Research Center College of Medicine Inje;
APHP Saint Antoine Hospital;
Geneva Platelet Group University of Geneva School of Medicine Division of Angiology and;
Department of Experimental and Clinical Medicine University of Florence Atherothrombotic Diseases;
Department of Cardiology and Cardiovascular Medicine University Hospital Tübingen;
Laboratory for Genotyping Development RIKEN Center for Integrative Medical Sciences;
Department of Cardiology and Cardiovascular Medicine University Hospital Tübingen;
Department of Cardiology Medical University of Vienna;
St Antonius Center for Platelet Function Research Department of Cardiology St Antonius Hospital;
Inova Center for Thrombosis Research and Drug Development. Inova Heart and Vascular Institute;
Sorbonne Universités UPMC Univ Paris 06 Institute of Cardiometabolism and Nutrition (ICAN);
Department of Medicine University of Maryland;
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology Stuttgart and University of Tübingen;
Department of Biomedical and Translational Informatics Geisinger Health System;
Department of Biomedical Data Science Stanford University;
Department of Medicine Program for Personalized and Genomic Medicine University of Maryland;
机译:基因组和候选基因氯吡格雷疗效方法使用药物动力学和临床终点 - 理性和设计国际氯吡格雷药物同盟(ICPC)
机译:CYP2C19但无PON1基因变异影响心肌梗死后患者的氯吡格雷药代动力学,药效学和临床疗效
机译:氯吡格雷药物:超越候选基因和基因组 - 宽协会研究
机译:全基因组方法来了解遗传变异在癌症易感性和临床结果中的作用。
机译:使用药效学和临床终点研究氯吡格雷功效的全基因组和候选基因方法-国际氯吡格雷药物基因组学联盟(ICPC)的原理和设计
机译:PON1 Q192R遗传多态性对不稳定心绞痛氯吡格雷氯吡格雷疗效和心血管事件的影响,以防止反复事件试验及心房颤动氯吡格拉尔试验与厄贝沙兰特预防血管事件